# Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study

*PRI Rank #12 · Topics and Trends in Most Cited Retinal Diseases and Treatments Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/retinal-diseases-and-treatments/2026/rank-12*

| Field | Value |
| --- | --- |
| Rank | #12 |
| 18m citations | 58 |
| Journal | The Lancet |
| Year | 2024 |
| DOI | 10.1016/s0140-6736(24)00310-6 |
| Corresponding authors | Peter A. Campochiaro |
| Institution | Johns Hopkins University, United States |

**Ranking page:** [Topics and Trends in Most Cited Retinal Diseases and Treatments Papers, Class of 2026](https://pri.pepkio.com/top-papers/retinal-diseases-and-treatments/2026)

**Paper link:** [10.1016/s0140-6736(24)00310-6](https://doi.org/10.1016/s0140-6736(24)00310-6)

## Topics

RGX-314 · Neovascular age-related macular degeneration · Subretinal injection · Gene therapy · dose-escalation study · Adeno-associated virus (AAV) vector · Anti-VEGF therapy · phase 1/2a clinical trial

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Retinal Diseases and Treatments Papers, Class of 2026. https://pri.pepkio.com/top-papers/retinal-diseases-and-treatments/2026. Accessed 2026-07-14.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```